Improving predictability of IgE-high type 2 chronic sinusitis with nasal polyps in the biologic era

BACKGROUND: Chronic rhinosinusitis (CRS) is an inflammatory disease that may require biological therapy. Omalizumab is an anti-IgE biologic that was recently approved by the FDA and Health Canada for use in severe CRS with nasal polyps (CRSwNP) recalcitrant to intranasal corticosteroids. Dosing is b...

Descripción completa

Detalles Bibliográficos
Autores principales: Heffernan, Austin, Phulka, Jobanjit, Thamboo, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128111/
https://www.ncbi.nlm.nih.gov/pubmed/35606866
http://dx.doi.org/10.1186/s40463-022-00580-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128111/
https://www.ncbi.nlm.nih.gov/pubmed/35606866
http://dx.doi.org/10.1186/s40463-022-00580-y

Ejemplares similares